TABLE 1.
The clinical characteristics of the enrolled AGC patients
| ID | Gender | Age | TNM | Primary Site | Metastatic Site | Differentiation | Lauren classification | HER2 IHC | EGFR IHC | Prior therapies |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 60 |
pT4N1 M0→M1 |
Cardia |
Liver Lung Bone |
Low to Medium | Mixed | 3+ | 1+ |
First: oxaliplatin + leucovorin calcium + tegafur Second: paclitaxel + loplatin Third: leucovorin calcium + 5‐fluorouracil + irinotecan + apatinib Fourth: docetaxel + capecitabine Fifth: paclitaxel liposomes |
| 2 | Female | 41 | pT3N3b M0→M1 | Antrum | Axillary LN Supraclavicular LN | Low to Medium | Diffused | 3+ | 1+ |
First: oxaliplatin + capecitabine Second: RC48‐ADC Third: irinotecan + trastuzumab |
| 3 | Male | 59 | pT4aN3aM0→M1 | Cardia |
Pleura Lung |
Low to Medium | Intestinal | 3+ | 3+ |
First line: S‐1 Second: paclitaxel + capecitabine |
| 4 | Male | 35 | cTxN+M1 | Antrum |
Liver Left adrenal gland Multiple LNs |
Medium | Intestinal | 3+ | 3+ |
First: docetaxel + oxaliplatin + apatinib Second: paclitaxel + oxaliplatin + capecitabine + trastuzumab |
| 5 | Male | 65 |
pT2N2 M0→M1 |
Antrum |
Liver Multiple LNs |
Low to Medium | Intestinal | 3+ | NA |
First: oxaliplatin + S‐1 Second: paclitaxel + capecitabine + trastuzumab |
LN, lymph nodes; T, size or direct extent of the primary tumor; N, degree of spread to regional lymph nodes; M, presence of distant metastasis.